Full Text
POSA145 Budget Impact of Zanubrutinib to Treat Relapsed or Refractory Marginal Zone Lymphoma from a Payer Perspective in the United States

Abstract

Authors

S Liu K Yang J Carter T Zimmerman B Tang

Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×